Evidence map›Paper›PMID 42126571›Full record

ArticleCancer chemotherapy and pharmacology2026

Pharmacokinetic and pharmacogenomic profile of capecitabine and oxaliplatin in a patient with gastric cancer undergoing hemodialysis: a case report.

Yuki Nakano, Toshinori Hirai, Nao Nishijo, Yugo Uematsu, Yoko Nakajima, Tomomi Ozaki, Ryoko Shibata, Asako Imada, Kazuya Naritomi, Fumihiko Ogata and 6 more

Abstract readCase Reports
PubMed Publisher
In one paragraph

Article in Cancer chemotherapy and pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Yuki NakanoDepartment of Pharmacy, Saga University Hospital, Saga, Japan, 5-1-1 Nabeshima, 849-0937. ynakano_1105@outlook.com.ORCID http://orcid.org/0000-0002-0235-7615
Toshinori Hirai *Department of Pharmacy, Institute of Science Tokyo Hospital, Tokyo, Japan.ORCID http://orcid.org/0000-0002-3898-2068
Nao NishijoFaculty of Pharmaceutical Sciences, Fukuoka University, Fukuoka, Japan.ORCID http://orcid.org/0009-0003-2898-6369
Yugo UematsuFaculty of Pharmacy, Kindai University, Osaka, Japan.ORCID http://orcid.org/0000-0001-5883-5842
Yoko NakajimaDepartment of Pediatrics, Fujita Health University School of Medicine, Aichi, Japan.
Tomomi OzakiDepartment of Nephrology, Saiseikai Futsukaichi Hospital, Fukuoka, Japan.
Ryoko ShibataDepartment of Nephrology, Saiseikai Futsukaichi Hospital, Fukuoka, Japan.
Asako ImadaDepartment of Nephrology, Saiseikai Futsukaichi Hospital, Fukuoka, Japan.
Kazuya NaritomiDepartment of Surgery, Saiseikai Futsukaichi Hospital, Fukuoka, Japan.
Fumihiko OgataFaculty of Pharmacy, Kindai University, Osaka, Japan.ORCID http://orcid.org/0000-0002-2755-8341
Naohito KawasakiFaculty of Pharmacy, Kindai University, Osaka, Japan.ORCID http://orcid.org/0000-0002-9412-0868
Tadashi HayamaFaculty of Pharmaceutical Sciences, Fukuoka University, Fukuoka, Japan.ORCID http://orcid.org/0000-0003-4329-8161
Masafumi YasunagaDepartment of Surgery, Saiseikai Futsukaichi Hospital, Fukuoka, Japan.
Kazuhiro TadaDivision of Nephrology and Rheumatology, Department of Internal Medicine, Faculty of Medicine, Fukuoka University, Fukuoka, Japan.
Hirotsugu HasuwaDepartment of Pharmacy, Saiseikai Futsukaichi Hospital, Fukuoka, Japan.
Kosuke MasutaniDivision of Nephrology and Rheumatology, Department of Internal Medicine, Faculty of Medicine, Fukuoka University, Fukuoka, Japan.ORCID http://orcid.org/0000-0001-9190-4600

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeAnticancer therapy for patients with gastric cancer on hemodialysis is challenging owing to varying pharmacokinetics and a lack of clinical trial data. This study aimed to evaluate the efficacy and safety of the capecitabine plus oxaliplatin (CapeOX) regimen in a 73-year-old male Japanese patient with stage IV gastric cancer (human epidermal growth factor receptor 2 negative) undergoing hemodialysis.

methodsThe selected chemotherapy regimen was approximately 50% dose of CapeOX (capecitabine 1500 mg/day on days 1-14 and oxaliplatin 100 mg/day 2-h infusion on day 1) every 3 weeks. Data on plasma drug concentrations, metabolic enzyme genetic polymorphisms, and clinical outcomes were analyzed.

resultsAnticancer therapy initially controlled the tumor; however, disease progression and cumulative peripheral neuropathy led to discontinuation after 17 cycles (approximately 12 months of treatment). Oxaliplatin exhibited a rebound increase after each dialysis session (dialyzer clearance [CL

conclusionThese findings suggest that appropriate dose reduction and genetic screening might be considered part of chemotherapy guidance to improve safety and effectiveness for patients with advanced gastric cancer undergoing hemodialysis.

Indexed as

Antineoplastic Combined Chemotherapy ProtocolsRenal DialysisStomach NeoplasmsAgedCapecitabineHumansMaleOxaliplatinCapecitabineOxaliplatinCapecitabineCapeOXGastric cancerHemodialysisOxaliplatinPharmacogenomicsPharmacokinetics

Identifiers

PMID42126571

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.